Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,409 across all filing types
Latest filing 2015-05-19 Share Issue/Capital Cha…
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Nombre d'actions et droits de vote au 18 mai 2015
Share Issue/Capital Change Classification · 98% confidence The document is a formal announcement from Innate Pharma, dated May 19, 2015, titled "NOUVEAU NOMBRE D'ACTIONS ET DE DROITS DE VOTE D'INNATE PHARMA AU 18 MAI 2015" (New number of shares and voting rights as of May 18, 2015). It explicitly cites French regulatory articles (Code de Commerce and AMF general regulation) requiring the publication of the total number of shares and voting rights. This content directly relates to changes in the company's capital structure and shareholder voting power, which is a specific type of corporate action disclosure. Among the provided codes, 'Share Issue/Capital Change' (SHA) is the most appropriate fit as it deals with the total number of shares and voting rights, which are fundamental components of the capital structure. It is not a general earnings release (ER), a management change (MANG), or a director's dealing (DIRS).
2015-05-19 French
INFORMATION FINANCIÈRE DU PREMIER TRIMESTRE 2015
Earnings Release Classification · 98% confidence The document is titled "INFORMATION FINANCIÈRE DU PREMIER TRIMESTRE 2015" (First Quarter 2015 Financial Information) and explicitly states, "Innate Pharma SA... publie aujourd'hui sa trésorerie pour le premier trimestre de l'année 2015." It provides key financial highlights (cash position, revenue) for the period ending March 31, 2015, and is dated May 5, 2015. This structure—a brief announcement of key figures for a specific interim period—is characteristic of an Earnings Release (ER). It is not the comprehensive Interim Report (IR) itself, but the initial release of results. The document length (4100 chars) supports this being a summary announcement rather than a full report. Q1 2015
2015-05-05 French
Financial update for the first quarter of 2015
Earnings Release Classification · 99% confidence The document is titled "FINANCIAL UPDATE FOR THE FIRST QUARTER OF 2015" and provides key financial figures (cash position, revenues) for the three months ended March 31, 2015. It is an announcement of period-end results, focusing on highlights rather than a comprehensive, detailed report like a 10-K or a full Interim Report (IR). The content structure—key bullet points followed by a brief narrative and CEO quote—is characteristic of an Earnings Release (ER). It is not a full transcript (CT), a presentation (IP), or a formal comprehensive quarterly report (IR). Q1 2015
2015-05-05 English
résultats AGM IPH
AGM Information Classification · 99% confidence The document is titled "RÉSULTATS DE L'ASSEMBLÉE GÉNÉRALE MIXTE DU 27 AVRIL 2015" (Results of the Mixed General Meeting of April 27, 2015). It details the voting results (quorum reached) and announces the appointment of a new board member (Véronique Chabernaud). This content directly relates to the proceedings and outcomes of an Annual General Meeting (AGM). Although it mentions the publication of the 2014 Annual Report ("Le Rapport d'activité et de responsabilité 2014 a été publié aujourd'hui"), the primary focus and bulk of the text concern the AGM results and governance changes, making AGM-R the most appropriate classification.
2015-04-28 French
IPH AGM Outcome
AGM Information Classification · 99% confidence The document is explicitly titled "OUTCOME OF ANNUAL GENERAL MEETING OF APRIL 27, 2015". It details the voting results (quorum, votes expressed) and announces the appointment of a new Supervisory Board member (Véronique Chabernaud) during the AGM. This content directly relates to the proceedings and outcomes of the Annual General Meeting. Therefore, the appropriate classification is AGM Information (AGM-R). Although it mentions other reports being available, the primary focus and title are on the AGM outcome.
2015-04-28 English
Innate Pharma and AstraZeneca announce global agreement
Regulatory Filings Classification · 90% confidence The document is a press release dated April 24, 2015, announcing a 'GLOBAL CO-DEVELOPMENT AND COMMERCIALISATION AGREEMENT' between Innate Pharma and AstraZeneca regarding the drug IPH2201. This announcement details financial terms, development plans, and strategic rationale. It is not a full annual report (10-K), an interim report (IR), or a formal regulatory filing like a DEF 14A or DVA. It is a significant business development announcement. Since the provided categories do not have a specific 'Business Development' or 'Press Release' code, I must select the closest fit. The content relates to financing/capital structure changes (up to $1.275 billion in payments and royalties) and strategic alliances. 'Capital/Financing Update' (CAP) is a possibility, but the primary focus is the agreement itself, not just the capital structure change. 'Regulatory Filings' (RNS) is the general fallback for miscellaneous announcements. Given the nature of a major partnership announcement detailing financial considerations, 'Capital/Financing Update' (CAP) is the most relevant category among the specific options, as it involves substantial financial commitments and milestones, even though it's framed as a partnership. However, since it is a general press release announcing a major corporate event (a deal), and not strictly a financing round or capital structure change, 'RNS' (Regulatory Filings/General Announcement) is often used for such material non-standard announcements when a specific 'Press Release' or 'M&A' code isn't available. Since this is a co-development agreement, not a takeover (TAR), and it involves significant financial terms, I will classify it as a general regulatory announcement/press release, which maps best to RNS, as it is a material public disclosure.
2015-04-24 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.